Listen: Is 23andMe Trading Your DNA? With Maria Liu from First Health Advisory Solutions
23andMe, the genetic testing company, just announced that it will be entering a 4-year partnership with pharmaceutical giant GlaxoSmithKline (GSK) to develop new drugs and therapies. As part of the partnership, 23andMe will share voluntarily-shared genetic data with the big pharma company. Maria Liu from First Health Advisory Solutions joined us to talk about…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Promoted content from First Health Advisory on MarketScale.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
23andMe, the genetic testing company, just announced that it will be entering a 4-year partnership with pharmaceutical giant GlaxoSmithKline (GSK) to develop new drugs and therapies.
As part of the partnership, 23andMe will share voluntarily-shared genetic data with the big pharma company. Maria Liu from First Health Advisory Solutions joined us to talk about the security concerns and potential worries that come with companies sharing medical data.
For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.
Follow us on social media for the latest updates in B2B!
Twitter – @HealthMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale
Part of this channel
First Health Advisory
News, updates, and expert insights from First Health Advisory.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.